Medication info

Emplazine Met Tablet 12.5/850 mg (Empagliflozin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›12.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Dongkuk Pharmaceutical Co., Ltd.
Appearance
Biconvex, oval, white tablet with a pink tint, film-coated
Packaging
60 tablets/box [(10 tablets/PTP x 6)], 10 tablets/box [(10 tablets/PTP x 1)], 60 tablets/bottle
Approval status
Active

MFDS item code 202302542 · Approved 2023.08.28

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient’s current dose of metformin. If empagliflozin 10 mg (total daily dose) is well tolerated but additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). Patients switching from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin to this medicine should receive their previous doses of empagliflozin and metformin. When this medicine is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this medicine, take it as soon as you remember. However, do not take twice the dose at one time; if this occurs, skip the missed dose. No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with a glomerular filtration rate (eGFR) below 60ml/min/1.73m2 [or creatinine clearance (CrCl) < 60 ml/min]. Because this medicine contains metformin, it must not be administered to patients with a glomerular filtration rate (eGFR) below 45 ml/min/1.73m2 or creatinine clearance (CrCl) below 45 ml/min (see Precautions for Use, 2. Patients Who Must Not Receive This Medicine, item 2)). This medicine may be administered to patients with an eGFR of 45-59 ml/ min/1.73m2 or CrCl of 45-59 ml/min only if they tolerate empagliflozin well and have no other conditions that may increase the risk of lactic acidosis. In these patients, the initial dose of metformin is 500mg or 850mg once daily, with a maximum dose of 500 mg twice daily; the permissible dose of empagliflozin is 10mg once daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Who Require Careful Administration, item 1)). If renal function declines to CrCl < 45 m/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Dongkuk Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Difficulties in blood glucose control in type 2 diabetes
  • cardiovascular diseases
View approved original text

This medication is used in conjunction with diet and exercise to help control blood glucose in adults with type 2 diabetes. It is particularly effective when blood glucose is not adequately controlled. Additionally, patients with cardiovascular diseases should be cautious while using this medication. This drug improves blood glucose control and assists in diabetes management.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient’s current dose of metformin. If empagliflozin 10 mg (total daily dose) is well tolerated but additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). Patients switching from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin to this medicine should receive their previous doses of empagliflozin and metformin. When this medicine is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this medicine, take it as soon as you remember. However, do not take twice the dose at one time; if this occurs, skip the missed dose. No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with a glomerular filtration rate (eGFR) below 60ml/min/1.73m2 [or creatinine clearance (CrCl) < 60 ml/min]. Because this medicine contains metformin, it must not be administered to patients with a glomerular filtration rate (eGFR) below 45 ml/min/1.73m2 or creatinine clearance (CrCl) below 45 ml/min (see Precautions for Use, 2. Patients Who Must Not Receive This Medicine, item 2)). This medicine may be administered to patients with an eGFR of 45-59 ml/ min/1.73m2 or CrCl of 45-59 ml/min only if they tolerate empagliflozin well and have no other conditions that may increase the risk of lactic acidosis. In these patients, the initial dose of metformin is 500mg or 850mg once daily, with a maximum dose of 500 mg twice daily; the permissible dose of empagliflozin is 10mg once daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Who Require Careful Administration, item 1)). If renal function declines to CrCl < 45 m/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Precautions

This medication can cause a rare but severe metabolic complication known as lactic acidosis, so it should not be administered to patients with poor kidney function or liver disease. When used in combination with other diabetes medications, hypoglycemia may occur, so blood glucose levels should be closely monitored. Patients with moderate or less impaired kidney function or suspected acute kidney injury should avoid using this medicine. In situations where the physical condition worsens rapidly, such as acute infection, heart failure, myocardial infarction, or shock, it may be necessary to temporarily discontinue the medication. Before and after receiving iodine contrast for examinations, this medication should be stopped to reduce the risk of kidney damage and lactic acidosis, and should be resumed only after verifying kidney function. Women who are pregnant or breastfeeding should not take this medication. Elderly patients are at higher risk for kidney function decline and fluid loss, so regular kidney function tests and monitoring of fluid status are necessary, and dosage adjustments may be required. This medication may increase the risk of urinary tract infections and genital infections, so immediate consultation with a healthcare professional is necessary if symptoms of infection occur. During treatment, attention should be paid to symptoms of hypoglycemia, especially if used in combination with insulin or sulfonylureas, as the risk of hypoglycemia is increased. This drug can lower vitamin B12 levels, so regular blood tests are required during long-term use. In case of overdose, serious side effects such as lactic acidosis may occur, so immediate medical attention is necessary upon any abnormal symptoms. Alcohol consumption may increase the risk of side effects from this medication, so it should be avoided during treatment. This medication may cause fluid loss, so caution is needed in the presence of dehydration, diarrhea, or vomiting, and it may be temporarily discontinued if necessary. Patients scheduled for surgery should stop this medication 48 hours prior to the procedure and resume it only after confirming normal kidney function.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • ketoacidosis
  • lactic acidosis
  • decreased vitamin B12 absorption
  • decreased fluid volume
  • nausea
  • vomiting
Show 166 more
  • diarrhea
  • abdominal pain
  • loss of appetite
  • abnormal liver function tests
  • hepatitis
  • alteration in taste
  • itching
  • rash
  • urticaria
  • erythema
  • angioedema
  • difficulty urinating
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • perineal necrosis
  • vomiting
  • diarrhea
  • gastrointestinal disorders
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • bowel hemorrhage
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • acute pyelonephritis
  • sepsis
  • subcutaneous abscess
  • adnexal-ovarian abscess
  • vestibular neuronitis
  • headache
  • positional vertigo
  • dizziness
  • drowsiness
  • myasthenia
  • chest discomfort
  • chest pain
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • weight loss
  • urinary stones
  • hematuria
  • overactive bladder
  • renal mass
  • urinary retention
  • urinary pain
  • abnormal urination
  • vulvar pruritus
  • benign prostatic hyperplasia
  • erectile dysfunction
  • atrophic vaginitis
  • cervical dysplasia
  • cervical inflammation
  • scrotal pain
  • sexual dysfunction
  • vaginal discharge
  • hypoglycemia
  • decreased appetite
  • obesity
  • hypoglycemia
  • diabetes
  • hyperlipidemia
  • hyponatremia
  • vitamin D deficiency
  • dermal cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • musculoskeletal pain
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • glaucoma
  • macular fibrosis
  • eye discomfort
  • eye congestion
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • hole-up retinal detachment
  • eyelid edema
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • age-related dyspnea
  • moist cough
  • allergic rhinitis
  • residual phlegm
  • cough
  • epistaxis
  • allergic rhinitis
  • skin laceration
  • rib fracture
  • ligamentous laxity syndrome
  • angina pectoris
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • arteriosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral artery occlusive disease
  • anxiety
  • depression
  • sleep disorders
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • orthostatic dizziness
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid mass
  • constipation
  • dyspepsia
  • abdominal pain
  • gastritis
  • gastrointestinal disorders
  • herpes zoster
  • unstable angina

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect against air and moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Biconvex, oval, white tablet with a pink tint, film-coated

Package unit

60 tablets/box [(10 tablets/PTP x 6)], 10 tablets/box [(10 tablets/PTP x 1)], 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.